Biolase, Inc.
BIOL
BIOL was delisted on the 18th of June, 2024.
35 hedge funds and large institutions have $27.4M invested in Biolase, Inc. in 2016 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 5 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3% less funds holding
Funds holding: 36 → 35 (-1)
10% less capital invested
Capital invested by funds: $30.4M → $27.4M (-$2.99M)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$47.5K |
| 2 |
BIP
Brandes Investment Partners
La Jolla,
California
|
+$31.6K |
| 3 |
CCM
Consonance Capital Management
New York
|
+$15.8K |
| 4 |
IA
IFP Advisors
Tampa,
Florida
|
+$15.8K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$15.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$44K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$31.6K |
| 3 |
Nomura Holdings
Tokyo,
Japan
|
-$19K |
| 4 |
BIM
BlackRock Investment Management
Wilmington,
Delaware
|
-$15.8K |
| 5 |
Morgan Stanley
New York
|
-$15.8K |
BIOL Hedge Fund Activity: Q2 2016 in Review
35 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Biolase, Inc. (BIOL) for Q2 2016, worth a combined $27.4M — down 9.8% from $30.4M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of BIOL and 4 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 3 added.
The largest buyer was Citadel Advisors, adding an estimated $47.5K. The largest seller was Virtu KCG Holdings, exiting entirely with an estimated $44K sold.
- 35 institutional investors held Biolase, Inc. (BIOL) as of Q2 2016, down from 36 in Q1 2016.
- Funds reported $27.4M of Biolase, Inc. stock for Q2 2016, down 9.8% quarter-over-quarter.
- 4 funds opened new Biolase, Inc. positions in Q2 2016 and 5 closed out, a net change of -1 holder.
- The largest Biolase, Inc. buyer in Q2 2016 was Citadel Advisors, an estimated $47.5K added.
- The largest Biolase, Inc. seller in Q2 2016 was Virtu KCG Holdings, an estimated $44K sold.
Based on aggregated 13F filings for Q2 2016.